109 related articles for article (PubMed ID: 2825672)
1. Platelet-activating factor (PAF) receptor antagonists inhibit mitogen-induced human peripheral blood T-cell proliferation.
Patrignani P; Valitutti S; Aiello F; Musiani P
Biochem Biophys Res Commun; 1987 Oct; 148(2):802-10. PubMed ID: 2825672
[TBL] [Abstract][Full Text] [Related]
2. Specific binding of platelet-activating factor (PAF) by human peripheral blood mononuclear leukocytes.
Ng DS; Wong K
Biochem Biophys Res Commun; 1988 Aug; 155(1):311-6. PubMed ID: 2843182
[TBL] [Abstract][Full Text] [Related]
3. Immune regulation by platelet-activating factor. I. Induction of suppressor cell activity in human monocytes and CD8+ T cells and of helper cell activity in CD4+ T cells.
Rola-Pleszczynski M; Pouliot C; Turcotte S; Pignol B; Braquet P; Bouvrette L
J Immunol; 1988 May; 140(10):3547-52. PubMed ID: 2834440
[TBL] [Abstract][Full Text] [Related]
4. Species difference in the specific receptors of platelet activating factor.
Hwang SB; Lam MH
Biochem Pharmacol; 1986 Dec; 35(24):4511-8. PubMed ID: 3024653
[TBL] [Abstract][Full Text] [Related]
5. Characterization of platelet-activating factor receptors on canine T lymphocytes.
Mangino MJ; Murphy MK; Weiss A; Anderson CB
J Immunol; 1993 Nov; 151(10):5310-8. PubMed ID: 8228226
[TBL] [Abstract][Full Text] [Related]
6. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.
Doebber TW; Wu MS; Biftu T
J Immunol; 1986 Jun; 136(12):4659-68. PubMed ID: 3011900
[TBL] [Abstract][Full Text] [Related]
7. High affinity receptor binding of platelet-activating factor in rat peritoneal polymorphonuclear leukocytes.
Hwang SB
Eur J Pharmacol; 1991 Apr; 196(2):169-75. PubMed ID: 1651872
[TBL] [Abstract][Full Text] [Related]
8. A specific, photolabile and irreversible antagonist (L662,025) of the PAF-receptor.
Hussaini IM; Shen TY
Biochem Biophys Res Commun; 1989 May; 161(1):23-30. PubMed ID: 2543410
[TBL] [Abstract][Full Text] [Related]
9. Platelet-activating factor and antagonists modulate DNA synthesis in human bone marrow stromal cell cultures.
Rougier F; Dupuis F; Cornu E; Dulery C; Praloran V; Denizot Y
J Lipid Mediat Cell Signal; 1997 Jul; 16(3):147-53. PubMed ID: 9246604
[TBL] [Abstract][Full Text] [Related]
10. Characterization of platelet-activating factor (PAF) receptor by specific binding of [3H]L-659,989, a PAF receptor antagonist, to rabbit platelet membranes: possible multiple conformational states of a single type of PAF receptors.
Hwang SB; Lam MH; Hsu AH
Mol Pharmacol; 1989 Jan; 35(1):48-58. PubMed ID: 2536468
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists.
Piper PJ; Stewart AG
Br J Pharmacol; 1987 Apr; 90(4):771-83. PubMed ID: 3034369
[TBL] [Abstract][Full Text] [Related]
12. Induction of IL-4 by platelet-activating factor.
Huang YH; Schäfer-Elinder L; Owman H; Lorentzen JC; Rönnelid J; Frostegård J
Clin Exp Immunol; 1996 Oct; 106(1):143-8. PubMed ID: 8870712
[TBL] [Abstract][Full Text] [Related]
13. [Mechanism of suppression of human peripheral blood lymphocyte proliferation by platelet activation factor].
Orlov SM; Vlasov AA; Lipatkina LIu; Dergousov AA; Kulikov VI
Biull Eksp Biol Med; 1989 Jul; 108(7):69-71. PubMed ID: 2804305
[TBL] [Abstract][Full Text] [Related]
14. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human lymphocyte proliferation and interleukin 2 production by platelet activating factor (PAF-acether): reversal by a specific antagonist, BN 52021.
Rola-Pleszczynski M; Pignol B; Pouliot C; Braquet P
Biochem Biophys Res Commun; 1987 Feb; 142(3):754-60. PubMed ID: 3493773
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor induces enhanced responses to platelet-activating factor and differentiation in human monocytic Mono Mac 6 cells.
Weber C; Aepfelbacher M; Haag H; Ziegler-Heitbrock HW; Weber PC
Eur J Immunol; 1993 Apr; 23(4):852-9. PubMed ID: 7681399
[TBL] [Abstract][Full Text] [Related]
17. Platelet-activating factor (PAF) enhances tumor necrosis factor production by alveolar macrophages. Prevention by PAF receptor antagonists and lipoxygenase inhibitors.
Dubois C; Bissonnette E; Rola-Pleszczynski M
J Immunol; 1989 Aug; 143(3):964-70. PubMed ID: 2545780
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1.
Proudfoot JM; Croft KD; Puddey IB; Beilin LJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):846-53. PubMed ID: 12626661
[TBL] [Abstract][Full Text] [Related]
19. Control of human T cell proliferation by platelet-activating factor.
Behrens TW; Goodwin JS
Int J Immunopharmacol; 1990; 12(2):175-84. PubMed ID: 2329011
[TBL] [Abstract][Full Text] [Related]
20. [3H]52770 RP, a platelet-activating factor receptor antagonist, and tritiated platelet-activating factor label a common specific binding site in human polymorphonuclear leukocytes.
Marquis O; Robaut C; Cavero I
J Pharmacol Exp Ther; 1988 Feb; 244(2):709-15. PubMed ID: 2831350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
